Pharma Equity Group AS (OCSE:PEG) Beneish M-Score: 0.00 (As of Jun. 26, 2026)


What is Pharma Equity Group AS Beneish M-Score?

Pharma Equity Group AS OCSE:PEG +2.82% Beneish M-Score is 0.00 as of Jun. 26, 2026. The stock has 3 warning signs investors should review. Among 831 Biotechnology companies, Pharma Equity Group AS ranks worse than 120336.82% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Pharma Equity Group AS's Beneish M-Score or its related term are showing as below:

During the past 13 years, the highest Beneish M-Score of Pharma Equity Group AS was 0.00. The lowest was 0.00. And the median was 0.00.

Pharma Equity Group AS Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Pharma Equity Group AS's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharma Equity Group AS Beneish M-Score Chart

Pharma Equity Group AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Pharma Equity Group AS Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

OCSE:PEG vs VRTX, REGN, ALNY: Beneish M-Score Comparison

For the Biotechnology subindustry, Pharma Equity Group AS's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharma Equity Group AS Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharma Equity Group AS's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Pharma Equity Group AS's Beneish M-Score falls into.


Pharma Equity Group AS Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Pharma Equity Group AS for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * +0.528 * +0.404 * +0.892 * +0.115 *
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * +4.679 * -0.327 *
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was kr33.89 Mil.
Revenue was kr0.00 Mil.
Gross Profit was kr0.00 Mil.
Total Current Assets was kr38.26 Mil.
Total Assets was kr38.90 Mil.
Property, Plant and Equipment(Net PPE) was kr0.64 Mil.
Depreciation, Depletion and Amortization(DDA) was kr0.31 Mil.
Selling, General, & Admin. Expense(SGA) was kr12.05 Mil.
Total Current Liabilities was kr8.83 Mil.
Long-Term Debt & Capital Lease Obligation was kr4.60 Mil.
Net Income was kr-25.38 Mil.
Gross Profit was kr0.00 Mil.
Cash Flow from Operations was kr-17.66 Mil.
 Total Receivables was kr41.94 Mil.
Revenue was kr0.00 Mil.
Gross Profit was kr0.00 Mil.
Total Current Assets was kr49.15 Mil.
Total Assets was kr49.42 Mil.
Property, Plant and Equipment(Net PPE) was kr0.27 Mil.
Depreciation, Depletion and Amortization(DDA) was kr0.24 Mil.
Selling, General, & Admin. Expense(SGA) was kr12.29 Mil.
Total Current Liabilities was kr8.63 Mil.
Long-Term Debt & Capital Lease Obligation was kr8.10 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(33.888 / 0) / (41.935 / 0)
= /
=

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(0 / 0) / (0 / 0)
= /
=

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (38.261 + 0.637) / 38.898) / (1 - (49.146 + 0.27) / 49.417)
=0 / 2.0E-5
=

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0 / 0
=

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.235 / (0.235 + 0.27)) / (0.311 / (0.311 + 0.637))
=0.465347 / 0.328059
=

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(12.05 / 0) / (12.285 / 0)
= /
=

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((4.598 + 8.827) / 38.898) / ((8.1 + 8.631) / 49.417)
=0.345133 / 0.338568
=

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-25.382 - 0 - -17.661) / 38.898
=-0.198493

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of 0.00 mean?
Pharma Equity Group AS (OCSE:PEG) has a Beneish M-Score of 0.00 as of Jun. 26, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Pharma Equity Group AS and its competitors. According to the industry distribution chart, Pharma Equity Group AS ranks #999999 out of 831 companies in the Biotechnology industry.
Is Pharma Equity Group AS's Beneish M-Score too high?
Pharma Equity Group AS's current Beneish M-Score is 0.00. Based on the distribution chart, Pharma Equity Group AS ranks #999999 out of 831 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Pharma Equity Group AS's Beneish M-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharma Equity Group AS ranks #999999 out of 831 companies for Beneish M-Score. This places Pharma Equity Group AS in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Pharma Equity Group AS and its competitors. Pharma Equity Group AS's current Beneish M-Score is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Equity Group AS stock overvalued right now?
Pharma Equity Group AS (OCSE:PEG) has a current Beneish M-Score of 0.00. The current Beneish M-Score is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Pharma Equity Group AS (OCSE:PEG), the current Beneish M-Score is 0.00 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pharma Equity Group AS Business Description

Address Slotsmarken 12, 1.th, Horsholm, DNK, DK-2970
Pharma Equity Group AS is an investment company specializing in the life science industry. The group is focused on an early investment in various life science companies that develop technologies and therapies that have the potential to improve human health and quality of life. The group specializes in early-stage investments in biotechnology, that are developing novel therapies for unmet medical needs. Its portfolio consists of companies dedicated to developing novel, effective treatments for diseases with patient and social impact for which current therapy is lacking or in need of improvement. Its drug candidates include RNX-011, RNX-021, RNX-022, RNX-023, RNX-041, and RNX-051 .